Results of Individual Patient Dosimetry in Peptide Receptor Radionuclide Therapy with 177Lu DOTA-TATE and 177Lu DOTA-NOC
Publication: Cancer Biotherapy & Radiopharmaceuticals
Volume 22, Issue Number 3
Abstract
One of the few treatment options for inoperable neuroendocrine tumors (NET) is peptide receptor radiotherapy with somatostatin analogs. In this study, we compared the dosimetric parameter uptake, half-life (kinetics), and mean absorbed organ and tumor doses of 177Lu DOTA-NOC and 177Lu DOTA-TATE. Methods: Ninety-five (95) post-therapeutic dosimetric assessments using 177Lu DOTA-TATE and 8 using 177Lu DOTA-NOC in 69 patients with neuroendocrine tumors with high somatostatin receptor expression (verified by Ga-68 DOTA-NOC positron emission tomography/computed tomography) were analyzed. Dosimetric calculations were performed according to the Medical Internal Radiation Dose scheme. Results: 177Lu DOTA-NOC showed a significantly (p ≤ 0.05; sign test) higher uptake for whole-body and normal tissue, as compared to 177Lu DOTA-TATE, leading to a significant higher whole-body dose of 0.07mGy/ MBq for DOTA-NOC, as compared to 0.05 mGy/MBq for DOTA-TATE. Renal and spleen uptake and radiation doses were not significantly higher for DOTA-NOC. The uptake in tumor lesions and the mean absorbed tumor dose were higher for DOTA-TATE. The red marrow dose was approximately 0.2 Gy. Conclusions: Our first results demonstrated that the higher in vitro affinity of DOTA-NOC leads to a higher uptake in normal tissues and, therefore, to an increase in the whole-body dose. The high interpatient variability of these results makes an individual patient dosimetry obligatory.
Get full access to this article
View all available purchase options and get full access to this article.
Information & Authors
Information
Published In
Cancer Biotherapy & Radiopharmaceuticals
Volume 22 • Issue Number 3 • June 2007
Pages: 406 - 416
PubMed: 17651048
Copyright
Mary Ann Liebert, Inc.
History
Published online: 26 July 2007
Published in print: June 2007
Topics
Authors
Metrics & Citations
Metrics
Citations
Export Citation
Export citation
Select the format you want to export the citations of this publication.
View Options
Get Access
Access content
To read the fulltext, please use one of the options below to sign in or purchase access.⚠ Society Access
If you are a member of a society that has access to this content please log in via your society website and then return to this publication.